Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, Jan. 3, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced the appointment of\n Richard Sachse, MD, PhD, as Senior Vice President, Chief Scientific\n Officer. Before joining Aeterna Zentaris, Dr. Sachse was Vice\n President, Head of Global Translational Medicine at Boehringer\n Ingelheim.\n\n\n\"We are very proud to welcome Dr. Sachse to our leadership team. As CSO,\n he will be responsible for all areas of our global research and\n development activities, while also serving on the corporate Operating\n Committee. In developing his industry career, Dr. Sachse has held\n increasingly responsible positions with several leading pharmaceutical\n companies, including Bayer, Schwarz Pharma, UCB and Boehringer\n Ingelheim, overseeing major drug development programs in a variety of\n different therapeutic areas, including oncology and endocrinology\",\n said David Dodd, President and CEO of Aeterna Zentaris.\n\n\nDr. Sachse added, \"I am delighted to get the opportunity to become part\n of Aeterna Zentaris' team and very much looking forward to contribute\n in advancing the Company's portfolio pipeline along the value chain. I\n believe that the combination of Aeterna Zentaris' highly qualified and\n motivated personnel, together with its strong scientific platform,\n holds much promise for the future success of our projects.\"\n\n\nDr. Sachse's Background\n\n\nDr. Sachse holds a degree in medicine from the\n Friedrich-Alexander-University Erlangen, in Germany, and a board\n certification in Clinical Pharmacology. With more than 20 years\n experience as a physician and scientist, he has extensive expertise in\n a variety of different therapeutic areas including endocrinology and\n oncology. In addition to registration studies, he is especially\n experienced in the design and implementation of translational programs\n to bridge research programs to the clinic, as well as in the design and\n implementation of clinical pharmacology programs, including all\n required profiling studies and activities, enabling successful\n registration of products at the international level.\n\n\nFrom 1996 to 2000, he was International Project Leader at the Bayer AG\n Institute for Clinical Pharmacology, and Principal Investigator at the\n Bayer Clinical Pharmacology Unit, impl...

More updates from Cosciens Biopharma Inc.